Health Care & Life Sciences » Biotechnology | Abeona Therapeutics Inc.

Abeona Therapeutics Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
4,449.00
26,778.00
14,526.00
21,873.00
27,319.00
56,671
Depreciation, Depletion & Amortization
3.00
11.00
551.00
825.00
741.00
2,360
Other Funds
4,688.00
24,764.00
9,621.00
8,261.00
5,789.00
8,240
Funds from Operations
236.00
2,003.00
4,354.00
12,787.00
20,789.00
46,071
Changes in Working Capital
237.00
392.00
6,069.00
227.00
2,146.00
6,960
Net Operating Cash Flow
1.00
1,611.00
10,423.00
13,014.00
22,935.00
39,111
Capital Expenditures
2.00
-
308.00
519.00
860.00
Sale of Fixed Assets & Businesses
-
-
3,697.00
-
-
Net Investing Cash Flow
2.00
-
3,389.00
519.00
860.00
Issuance/Reduction of Debt, Net
-
400.00
400.00
-
-
Net Financing Cash Flow
29.00
12,707.00
35,652.00
42,537.00
92,403.00
Net Change in Cash
28.00
11,096.00
28,618.00
29,004.00
68,608.00
Free Cash Flow
1.00
1,611.00
10,731.00
13,533.00
23,795.00
Change in Capital Stock
29.00
12,307.00
36,052.00
42,537.00
92,403.00

About Abeona Therapeutics

View Profile
Address
1330 Avenue of the Americas
New York New York 10019
United States
Employees -
Website http://www.abeonatherapeutics.com
Updated 07/08/2019
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Dallas, TX.